33 press releases indexed under healthcare.
WASHINGTON, May 29, 2026 /PRNewswire/ -- Happy the elephant, who was held captive at the Bronx Zoo for almost half a century, has been euthanized due to deteriorating health, the zoo has reported. Happy and Patty – the other solitary housed elephant at the Bronx Zoo – have long been the...
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
Phase 1a/b Study for Selective Brain-Penetrant CDK2 Inhibitor AL-605 doses patients; Selective Brain-Penetrant CDK4 Inhibitor AL-433 on Track for First-in-Human Study SAN DIEGO, May 29, 2026 /PRNewswire/ -- Alaw Therapeutics, Inc. ("Alaw"), a clinical-stage biotechnology company...
World's Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 29, 2026 /PRNewswire/ -- RingConn officially launches the Gen 3 Smart Ring globally on May 29th, bringing vascular insights and continuous tracking into a refined ultra-lightweight wearable experience. Following...
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for PMX, the Company’s endotoxin removal therapy for patients with endotoxic septic shock (“ESS”).
REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical...
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29,...
World's Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 29, 2026 /PRNewswire/ -- RingConn officially launches the Gen 3 Smart Ring globally on May 29th, bringing vascular insights and continuous tracking into a refined ultra-lightweight wearable experience. Following...
SAN DIEGO, May 28, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, released updated positive Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L)...
TREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics...
WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and Chief Executive Officer, effective June 30, 2026, following eight years of leadership that established Allogene as a leader in the development of off-the-shelf cell therapies. Dr. Chang will continue to serve on the Company’s Board of Directors.